Gruenenthal Gmbh

Richter Gedeon Nyrt.

Grunenthal Gmbh

Christa Kneip

Stefan Schunk

Ruth Jostock

Melanie Reich

Tieno Germann

Michael Engels

Stefan Oberboersch

Jean De Vry

Johannes Schneider

Georg Schramm

Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

Bradykinin 1 receptor modulating compounds

The present invention relates to the use of 3&#x3b2;-hydroxychlormadinone acetate (17&#x3b1;-acetoxychloropregna-4,6-dien-3&#x3b2;-ol-20-one) and/or 3&#x3b1;-hydroxychlormadinone acetate (17&#x3b1;-acetoxychloropregna-4,6-dien-3&#x3b1;-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3&#x3b2;-hydroxychlormadinone acetate and/or 3&#x3b1;-hydroxychlormadinone acetate.

3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

Substituted spiro-amide compounds

Growing community of inventors

Aachen, Germany

Christa Kneip